Logo-ps
Pharm Sci. 2022;28(3): 443-448.
doi: 10.34172/PS.2021.57

Scopus ID: 85133265760
  Abstract View: 689
  PDF Download: 360

Research Article

Development of a Nanocluster-Based Platform for Determination of Sofosbuvir

Zahra Karimzadeh 1,2 ORCID logo, Abolghasem Jouyban 1,3 ORCID logo, Elaheh Rahimpour 1,4* ORCID logo

1 Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Food and Drug Safety Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
*Corresponding Author: Corresponding Author: Elaheh Rahimpour, E-mail: , Email: rahimpour_e@yahoo.com

Abstract

Background: Sofosbuvir is a potent direct-acting antivirus agent that has been listed as a promising medicine for the treatment of all genotypes of hepatitis C virus. As antiviral drugs could be metabolized to their associated compounds and toxicologically and pharmacologically interfere with the parent drugs, identifying the therapeutic range of drugs would be notable.

Methods: In the current study, copper nanoclusters (Cu NCs) are synthesized during the reduction of copper nitrate with hydrazine hydrate in a protected media and used as a nanoprobe for the determination of sofosbuvir in plasma samples. Herein, synchronous fluorescence spectroscopy (SFS) is used for monitoring of fluorescence variation of nanoprobe owing to the excessive benefits compared with the traditional fluorescence.

Results: SFS peak of Cu NCs has appeared at 355 nm with ∆λ=80 nm which is decreased in the presence of sofosbuvir. To optimize the reaction factors, a response surface methodology is used and in the optimized conditions, a linear concentration-response plot is obtained in a range of 0.05-6.0 µg mL−1 with a limit of detection of 0.0147 µg mL−1.

Conclusion: The developed method also reveals good repeatability and selectivity for sofosbuvir in plasma samples.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 690

Your browser does not support the canvas element.


PDF Download: 360

Your browser does not support the canvas element.

Submitted: 28 Jul 2021
Revision: 05 Sep 2021
Accepted: 07 Sep 2021
ePublished: 11 Sep 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)